RecruitingPhase 2NCT04629547
Sleep Trial to Prevent Alzheimer's Disease
Sponsor
Washington University School of Medicine
Enrollment
200 participants
Start Date
May 25, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Eligibility
Min Age: 65 Years
Plain Language Summary
Simplified for easier understanding
This study is testing whether treating sleep disorders — particularly sleep apnea — in older adults can reduce the risk of developing Alzheimer's disease. It focuses on people who currently show no signs of dementia, with the goal of preventing cognitive decline before it starts.
**You may be eligible if...**
- You are 65 years old or older
- You currently show no signs of dementia (CDR score of 0)
- You are willing and able to participate in study procedures, including a sleep test
**You may NOT be eligible if...**
- You have restless legs syndrome, narcolepsy, or other sleep disorders
- You have untreated moderate-to-severe sleep apnea
- You use a CPAP/sleep apnea device but use it less than 4 hours a night most nights
- Your blood Alzheimer's biomarker test (p-tau 217) is below a certain threshold
- You have had a stroke or have chronic kidney disease
- You have liver problems or HIV
- You have a history of substance or alcohol abuse in the past 6 months
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSuvorexant 20 mg
Suvorexant 20mg will be taken nightly for 24 months.
DRUGPlacebo
Placebo will be taken nightly for 24 months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04629547
Related Trials
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT0684732135 locations
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787288 locations
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732157 locations
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
NCT07011745140 locations
[18F]PI-2620 Phase 3 Histopathological Study
NCT0564168825 locations